Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30822716 | 0.78 | RAB9A (0.52) | POLBRAB9A | |
| SCHEMBL31241183 | 0.76 | POLB (0.67) | POLBHTTROCK1FGFR1MAPT | |
| SCHEMBL3148726 | 0.75 | POLB (0.56) | POLBHTTROCK1FGFR1MAPT | |
| SCHEMBL2147667 | 0.74 | POLB (0.70) | POLBHTTROCK1FGFR1LCK | |
| SCHEMBL31722849 | 0.74 | POLB (0.70) | POLBHTTROCK1FGFR1LCK | |
| SCHEMBL29744972 | 0.73 | POLB (1.00) | POLBHTTROCK1FGFR1MAPT | |
| SCHEMBL1346814 | 0.73 | POLB (1.00) | POLBHTTROCK1FGFR1MAPT | |
| SCHEMBL9338772 | 0.71 | POLB (0.96) | POLBHTTROCK1FGFR1MAPT | |
| SCHEMBL20741465 | 0.71 | TLR7 (0.49) | POLBROCK1 | |
| SCHEMBL3417306 | 0.71 | HTT (0.73) | POLBHTTROCK1FGFR1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020150545-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE WNT/B-CATENIN SIGNALING PATHWAY | SAMUMED, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| EP-2041119-B1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2017-05-10 | — | — | EP | disclosed |
| EP-2970210-B1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | Celon Pharma Sa (PL) | 2017-01-04 | — | — | EP | disclosed |
| US-20160039794-A1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | CELON PHARMA S.A. (PL) | 2016-02-11 | — | — | US | disclosed |
| EP-2970210-A1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | CELON PHARMA S.A. (PL) | 2016-01-20 | — | — | EP | disclosed |
| US-9126969-B2 | Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2015-09-08 | — | — | US | disclosed |
| US-9126969-B2 | Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2015-09-08 | — | — | US | disclosed |
| WO-2014141015-A1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | CELON PHARMA S.A. (PL) | 2014-09-18 | — | — | WO | disclosed |
| EP-2041119-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | Aventis Pharma S.A. (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-7507486-B2 | Organic phosphorescent light emitting device | EASTMAN KODAK COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1966213-A1 | TRICYCLIC LACTAM DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008099075-A1 | 2-ANILINO-4-HETEROARYL PYRIMIDINE DERIVATIVES, AND PREPARATION THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS, AND IN PARTICULAR IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | disclosed |
| EP-1920479-A1 | ORGANIC PHOSPHORESCENT LIGHT EMITTING DEVICE | EASTMAN KODAK COMPANY (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008022747-A1 | TRICYCLIC LACTAM DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008003857-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007068465-A1 | TRICYCLIC LACTAM DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007027440-A1 | ORGANIC PHOSPHORESCENT LIGHT EMITTING DEVICE | EASTMAN KODAK COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070048546-A1 | Organic phosphorescent light emitting device | EASTMAN KODAK COMPANY | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039794-A1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | NR0B2, NR2C2, NR4A3 | POLB 1314/4885HTT 4737/4885ROCK1 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.